New growth hormone drug enters first human tests

NCT ID NCT07016802

Recruiting now Disease control Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a new drug called GenSci134 in healthy adults and patients with adult growth hormone deficiency. The main goal is to check safety and how well the body tolerates it. Researchers will give single or multiple doses and watch for side effects. It is a small study with 64 participants, so results are very preliminary.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GenSci134 (a new growth hormone drug)
What this could lead to: If successful, this could lead to a new treatment option for adults with growth hormone deficiency, potentially offering better dosing or fewer side effects.
What could go wrong: This is a very early Phase 1 trial with only 64 participants, focused on safety. It is too small and early to know if the drug works or is safe long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADULT GROWTH HORMONE DEFICIENCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pituitary dwarfism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADULT GROWTH HORMONE DEFICIENCY SAFETY TOLERABILITY

Contacts and locations

Locations

Peking University Third Hospital
RECRUITING

Beijing, Beijing Municipality, 100083, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.